0000000000155583

AUTHOR

Khan A

showing 4 related works from this author

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016

2018

Background: The lifetime risk of stroke has been calculated in a limited number of selected populations. We sought to estimate the lifetime risk of stroke at the regional, country, and global level using data from a comprehensive study of the prevalence of major diseases.Methods: We used the Global Burden of Disease (GBD) Study 2016 estimates of stroke incidence and the competing risks of death from any cause other than stroke to calculate the cumulative lifetime risks of first stroke, ischemic stroke, or hemorrhagic stroke among adults 25 years of age or older. Estimates of the lifetime risks in the years 1990 and 2016 were compared. Countries were categorized into quintiles of the sociode…

MalePercentileNutrition and DiseaseDisease030204 cardiovascular system & hematologyGlobal HealthSocioeconomic FactorGlobal Burden of Disease0302 clinical medicinepreventionVoeding en ZiekteCause of DeathGlobal healthStrokePOPULATIONCause of deathAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceMedicine (all)11 Medical And Health SciencesGeneral MedicineMiddle Agedlifetime riskstroke3142 Public health care science environmental and occupational health3. Good healthStrokeGBD 2016 Lifetime Risk of Stroke CollaboratorsFemaleBURDENLife Sciences & BiomedicineResearch ArticleHumanAdultRiskPopulationGlobal Burden of Disease (GBD)03 medical and health sciencesMedicine General & InternalAge DistributionGeneral & Internal MedicinemedicineHumansLife SciencePoint estimationcardiovascular diseasesSex DistributioneducationVLAGAgedScience & TechnologyHYPERTENSIONbusiness.industrymedicine.diseaseSocioeconomic Factorsbusiness030217 neurology & neurosurgeryRCDemography
researchProduct

Body mass index and complications following major gastrointestinal surgery

2018

Aim Previous studies reported conflicting evidence on the effects of obesity on outcomes after gastrointestinal surgery. The aims of this study were to explore the relationship of obesity with major postoperative complications in an international cohort and to present a meta-analysis of all available prospective data.Methods This prospective, multicentre study included adults undergoing both elective and emergency gastrointestinal resection, reversal of stoma or formation of stoma. The primary end-point was 30-day major complications (Clavien-Dindo Grades III-V). A systematic search was undertaken for studies assessing the relationship between obesity and major complications after gastroint…

MaleobesityMultivariate analysisGastrointestinal DiseasesIMPACTSettore MED/18 - CHIRURGIA GENERALEBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complications; Gastroenterologydigestive tractTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineGastrointestinal tractRisk FactorsMedicineProspective StudiesProspective cohort studyBody mass indexBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complications; Aged; Europe; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Obesity; Postoperative Complications; Prospective Studies; Risk Factors; Body Mass IndexGastrointestinal NeoplasmsOUTCOMESPostoperative complications; body mass index; body weight; digestive tract; gastrointestinal tract; obesityGastroenterologyMiddle AgedBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complicationsEurope030220 oncology & carcinogenesisMeta-analysisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortFemale030211 gastroenterology & hepatologyCohort studymedicine.medical_specialtybody mass indexMalignancyNO03 medical and health sciencesPostoperative complicationsbody weightSDG 3 - Good Health and Well-beingHumansDigestive tractObesityAgedbusiness.industrypostoperative complications; obesity; digestive tract; gastrointestinal tract; body mass index; body weightMORTALITYBody weightmedicine.diseaseObesitySettore MED/18SurgeryPostoperative complicationPostoperative Complications Obesity Digestive Tract Gastrointestinal Tract Body Mass Index Body Weight.gastrointestinal tractbusinessBody mass indexColorectal Disease
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct